solute carrier family 29 member 4 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored SLC29A4P2 profile across patient tissues and cancer cell-line models. SLC29A4P2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC29A4P2 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, SLC29A4P2 RNA expression shows 5,444 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BRCA, and STAD as cancer lineages where SLC29A4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC29A4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC29A4P2 survival associations across molecular data types. SLC29A4P2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC29A4P2 RNA expression–survival associations across cancer types. High SLC29A4P2 expression shows unfavorable associations in ACC, UVM, COAD, LUAD, READ and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC29A4P2 RNA expression.
This table summarizes SLC29A4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SLC29A4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC29A4P2 shows lower tumor expression in BRCA and THCA and higher tumor expression in HNSC, KIRC and PRAD. The BRCA box plot shows higher SLC29A4P2 RNA expression in normal versus tumor tissue (log2 FC = −0.007, t-test p = .003).
This table shows molecular features associated with SLC29A4P2 in patient tissues and cancer cell lines. In patient samples, SLC29A4P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
